Introduction {#s1}
============

The expansion of access to antiretroviral therapy (ART) has averted millions of deaths for those who are infected with HIV ([@B9]; [@B33]). In the current World Health Organization (WHO) guidelines, the recommended initial therapy for patients infected with HIV-1 is a combination ART that includes two nucleoside reverse-transcriptase inhibitors (NRTIs) and nonnucleoside reverse-transcriptase inhibitors (NNRTIs) or a ritonavir-boosted PI (PI/r) ([@B34]). When NRTIs are used in first-line or second-line therapy regimens, the tolerability, safety, and toxicity profiles are limiting. For example, the combination of tenofovir (TDF) and emtricitabine (FTC) could cause renal and bone complications ([@B21]; [@B14]; [@B3]). These shortcomings have led to research on alternative combinations without NRTIs to expand treatment options. The WHO's proposed public health approach provides treatment for millions of people in low-income and middle-income countries with weak health systems ([@B35] revision. <http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf> (accessed April 1, 2013)\]. This approach emphasizes the importance of simple, effective, safe, and tolerable treatment that can be performed by trained, non-health-care workers in accordance with simple procedures. In various formulations, a simplified approach can also reduce the need for multiple drug stocks ([@B11]). Some trials have found the efficacy and safety of ritonavir-boosted lopinavir (LPV/r) plus raltegravir (RAL) to be largely similar to that of LPV/r plus NRTIs ([@B8]; [@B23]; [@B29]). RAL has been increasingly used clinically in first-line and second-line ART regimens because it is more efficacious and better tolerated than NRTIs.

RAL was launched in 2007 as a first integrase inhibitor ([@B6]; [@B24]) it was efficacious and generally well tolerated in patients infected with HIV-1 ([@B20]; [@B5]; [@B18]) and could serve as the third drug in a combination ART regimen ([@B4]; [@B19]). HIV infection is a chronic disease, and affected patients will receive life-long therapy. In treatment-experienced patients with multidrug-resistant HIV compared with patients who receive placebo plus optimized background therapy (OBT), RAL with OBT has been shown to be well tolerated, safe, and effective in producing viral suppression in treatment-experienced patients at 16 and 24 weeks ([@B10]). PI/r plus RAL was included as an alternative regimen in the 2016 WHO treatment guidelines ([@B34]). The WHO-preferred PI/r drugs are atazanavir, lopinavir, and darunavir on the basis of efficacy and tolerability ([@B32]). Although increasing clinical evidence suggests that RAL plus PIs/r is an effective regimen ([@B27]) to our knowledge, no meta-analysis has quantified the efficacy and safety of RAL plus PI/r compared with the efficacy and safety of two NRTIs plus PI/r.

This study aims to systematically evaluate the efficacy and safety of RAL-based simplified dual therapy (DT) in ART-naive and ART-experienced patients. We reviewed the literature to estimate differences in viral suppression, CD4 counts, adverse events, mortality, and adherence. These results will provide evidence-based recommendations for AIDS therapy.

Methods {#s2}
=======

This review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement ([@B22]), registration number CRD42017082468 (<https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42017082468>).

Data Sources {#s2_1}
------------

Systematic searches included all of the literature regarding RAL published in PubMed, MEDLINE, Web of Science, and Embase from January 1, 2004, to September 11, 2019. We searched for clinical trials using the following terms: "HIV," "integrase inhibitors," and "protease inhibitor"; only studies published in English were considered.

Literature Inclusion and Exclusion Criteria {#s2_2}
-------------------------------------------

Only randomized controlled trials (RCTs) (n \> 10) were included in the meta-analysis, and all patients had been treated with PIs/r with RAL or PIs/r with two NRTIs. The included studies incorporated treatment-experienced adults and adolescents with HIV who had failed a WHO-recommended first-line NRTI-based regimen and switched to an RAL-based simplified regimen. We excluded the following: (1) reviews, letters, case observations studies, and retrospective studies; (2) animal and *in vitro* experiments; (3) HIV-1 patients who were younger than 12 years old or pregnant; and (4) studies not including baseline CD4 cell counts or viral load monitoring.

Study Selection and Exclusion Processes {#s2_3}
---------------------------------------

Two investigators (YH and XH), working independently, scanned all titles and abstracts and excluded irrelevant articles. When divergence between the two investigators occurred, YC or HW arbitrated the dispute. Two investigators assessed the eligibility of full-text papers according to the inclusion and exclusion criteria. Then, data on the article's characteristics, interventions at baseline, HIV RNA loads, CD4 cell counts, grade 3 or 4 adverse events, adherence, mortality, and drug resistance were independently extracted from the final list of selected eligible studies. The outcomes were chosen according to the WHO guidelines ([@B34]) and included viral suppression, the mean change in CD4 cell counts, grade 3 or 4 adverse events, drug resistance, mortality, and adherence. Any discrepancies between the investigators were resolved through discussion, and Dr. Chen arbitrated the dispute until a consensus was reached.

Study Quality Assessment {#s2_4}
------------------------

The methodological quality of the RCTs was assessed by the Cochrane risk of bias tool; there were seven domains ([@B15]). Study quality was recorded as "high risk," "unclear risk," or "low risk." Studies meeting all criteria were considered to have a low risk of bias, whereas those meeting none of the criteria were considered to have a high risk of bias. Otherwise, studies were considered to have an unclear risk of bias.

Statistical Analysis {#s2_5}
--------------------

Statistical analyses were performed with RevMan 5.3 software (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2014). Dichotomous and continuous data are expressed as risk ratios (RRs) and mean differences (MDs), respectively, with 95% confidence intervals (95% CIs). Statistical heterogeneity was assessed by Cochrane's Q test. If the heterogeneity test result was P ≥ 0.10 and I^2^ ≤ 50%, the studies were considered homogenous, and the fixed effect model was selected. In contrast, studies that were not homogeneous were assessed using a random-effects model.

Results {#s3}
=======

Characteristics of the Included Studies {#s3_1}
---------------------------------------

A total of 2,610 publications from four databases were identified by the initial screening; of these, Eight eligible articles were included in this meta-analysis ([@B28]; [@B16]; [@B11]; [@B25]; [@B26]; [@B1]; [@B17]; [@B13]) ([**Figure 1**](#f1){ref-type="fig"}). These trials were published from 2011 to 2018. Of these eight articles, six examined treatment with a combination of RAL and LPV/r, One examined treatment with RAL in combination with atazanavir/ritonavir (ATV/r), and one examined treated with a combination of RAL and darunavir/ritonavir (DRV/r) ([**Table 1**](#T1){ref-type="table"}). In this analysis, we included ART-naive patients and ART-experienced patients.

![Flow diagram of the study selection. As shown, our initial searches yielded 2,610 records. The full texts of 1,189 articles were retrieved for detailed assessment after exclusion. Of these, 1,181 studies were subsequently excluded because they failed to meet the inclusion criteria; eight eligible studies were identified.](fphar-10-01225-g001){#f1}

###### 

Characteristics of the included studies.

  Reference   Patient age   Cases   Interventions   Treatment (weeks)   Patients                                                         
  ----------- ------------- ------- --------------- ------------------- --------------- ------------------- ------- --------------- ---- --------------------------
  [@B16]      ≥18           94      RAL+ATV/r       74.6%               166 ± 133.9     ATV/r+RTV+TDF/FTC   63.3%   127 ± 95.9      24   ART-naive patients
  [@B28]      ≥18           206     RAL +LPV/r      83.2%               214.9           LPV/r+TDF/FTC       84.8%   245             4    ART-naive patients
  [@B25]      \> 12         859     RAL +LPV/r      66.1%               260.0 ± 185.5   LPV/r+NRTIs         65.0%   234.0 ± 208.1   96   ART-experienced patients
  [@B1]       ≥16           541     RAL +LPV/r      70.0%               228.7 ± 184.6   LPV/r+NRTIs         67.5%   201.7 ± 193.7   96   ART-experienced patients
  [@B11]      ≥16           541     RAL +LPV/r      71.1%               167.4 ± 142.1   LPV/r+NRTIs         70.5%   132.5 ± 146.0   48   ART-experienced patients
  [@B17]      ≥18           515     RAL +LPV/r      82.3%               199.0 ± 131.2   LPV/r+NRTIs         80.4%   190.0 ± 133.6   48   ART-experienced patients
  [@B26]      ≥18           805     RAL+DRV/r       84.8%               266(250-283)    DRV/r +TDF--FTC     80.9%   268(250-284)    96   ART-naive patients
  [@B13]      \> 12         859     RAL +LPV/r      72.0%               296.0 ± 258.9   LPV/r+NRTIs         75.0%   290.0 ± 247.6   24   ART-experienced patients

RAL, raltegravir; LPV/r, ritonavir-booted lopinavir; NRTI, nucleoside reverse transcriptase inhibitor; DRV/r, ritonavir-booted darunavir; ATV/r, ritonavir-booted atazanavir.

Methodological Quality of the Included Trials {#s3_2}
---------------------------------------------

These articles are all based on randomized, open-label, noninferiority, and multicenter trials. According to the Cochrane risk of bias estimation, randomized participant allocation was mentioned in all trials; six trials ([@B28]; [@B11]; [@B25]; [@B26]; [@B1]; [@B13]) used a specific method, whereas two trials ([@B16]; [@B17]) were defined as "high risk" for using an unclear randomization method. Three trials ([@B11]; [@B26]; [@B1]) blinded the participants and investigators to the treatment, four trials ([@B16]; [@B25]; [@B17]; [@B13]) only blinded the participants to the treatment, and one trial ([@B28]) did not mention blinding. All trials reported complete outcome data, and there was no selective reporting. Five trials ([@B11]; [@B25]; [@B26]; [@B17]; [@B13]) were low risk in terms of other biases ([**Figure 2**](#f2){ref-type="fig"}).

![Quality assessment of the studies selected for systematic review. The risk of bias was used to assess the quality of the randomized controlled trials, and the majority of studies were found to be of low quality.](fphar-10-01225-g002){#f2}

Outcome Measures {#s3_3}
----------------

### Plasma HIV-1 RNA Viral Load {#s3_3_1}

The results of the meta-analysis in terms of the viral suppression with RAL plus PIs/r (DT group) versus PIs/r plus two NRTIs (TT group) indicated comparable effects of the different regimens (viral suppression using 50 copies per ml). Two studies ([@B16]; [@B13]) that included 864 participants reported outcomes and indicated a significant difference between the two regimes at 24 weeks. The effect of DT was greater than that of TT (P = 0.69, I^2^ = 0%) \[risk ratio 1.11, 95% CI \[1.02, 1.21\], P = 0.01\] ([**Figure 3**](#f3){ref-type="fig"}). The average viral suppression rate in the TT group was 69% (95% CI: 65%--74%), whereas it was 77% (95% CI: 73%--80%) in the DT group ([**Table 1**](#T1){ref-type="table"}). At 48 weeks and 96 weeks, the efficacy in viral suppression was not different between the TT and DT groups (risk ratio 1.01, 95% CI 0.95--1.07, P = 0.73; risk ratio 1.03, 95% CI 0.98--1.08, P = 0.23, respectively) ([**Figure 3**](#f3){ref-type="fig"}). The viral suppression rate in the TT group was 78% at 48 weeks and 71% (95% CI: 61%--82%) at 96 weeks, whereas the viral suppression rate in the DT group was 79% (95% CI: 71%--87%) at 48 weeks and 74% (95% CI: 61%--86%) at 96 weeks ([**Table 1**](#T1){ref-type="table"}). A funnel plot was used to express the publication bias. The plots were symmetrical, suggesting that there was no obvious publication bias.

![Forest plot comparing viral suppression with the two therapy regimens. (1) RAL = raltegravir. PIs/r = ritonavir-boosted protease inhibitor. NRTI = nucleoside or nucleotide reverse transcriptase inhibitor. (2) Study item displayed as the first author with the publication year. (3) I^2^ and P are the criteria of the heterogeneity test, with the ---◆---pooled odds ratio, ---¦--- odds ratio and 95% confidence interval.](fphar-10-01225-g003){#f3}

### CD4 Cell Counts {#s3_3_2}

Among the eight studies, five studies ([@B28]; [@B11]; [@B25]; [@B1]; [@B17]) contributed to the CD4 cell counts analysis. One ([@B28]) of the five studies used the median to express the average CD4 cell counts. The findings showed that increases in mean CD4 counts were significantly higher in the DT group than in the TT group at 48 weeks and 96 weeks (mean difference 9.05, 95% CI 7.96--10.13, P \< 0.01; mean difference 9.12, 95% CI 8.04--10.20, P = 0.01, respectively). This strategy showed no significant heterogeneity when the DT group was compared with the TT group at 96 weeks(P = 0.96, I^2^= 0%). However, at 48 weeks, there was significant heterogeneity between the two groups (P = 0.04, I^2^= 77%). In short, compared with the current standard of therapy regimen, simplified therapy showed a significant efficacy in terms of immune reconstruction ([**Figure 4**](#f4){ref-type="fig"}).

![Forest plot comparing CD4 cell counts with simplified and traditional treatment therapy in HIV-1 patients. (1) RAL = raltegravir. PIs/r = ritonavir-boosted protease inhibitor. NRTI = nucleoside or nucleotide reverse transcriptase inhibitor. (2) Study item displayed as the first author with the publication year. (3) I^2^ and P are the criteria of the heterogeneity test, with the ---◆---pooled odds ratio, ---¦--- odds ratio and 95% confidence interval.](fphar-10-01225-g004){#f4}

### Adverse Events {#s3_3_3}

Regarding adverse events, we chose studies that reported grade 3 or 4 adverse events. The investigators found no significant differences in adverse events between the DT and TT groups at 96 weeks \[risk ratio 0.97, 95% CI (0.80, 1.19), P = 0.80\] ([**Figure 5**](#f5){ref-type="fig"}). At 48 weeks, there were significantly fewer adverse events in the DT group than in the TT group (risk ratio 0.70, 95% CI \[0.54, 0.91\], P \< 0.01).

![Forest plot comparing grade 3 or 4 adverse events with the RAL-based simplified regimen and the PIs/r-based traditional regimen in HIV-1 patients. (1) RAL = raltegravir. PIs/r = ritonavir-boosted protease inhibitor. NRTI = nucleoside or nucleotide reverse transcriptase inhibitor. (2) Study item displayed as the first author with the publication year. (3) I^2^ and P are the criteria of the heterogeneity test, with the ---◆---pooled odds ratio, ---¦--- odds ratio and 95% confidence interval.](fphar-10-01225-g005){#f5}

### Drug Resistance {#s3_3_4}

Drug resistance mutations were reported in eight studies. Seven ([@B28]; [@B16]; [@B11]; [@B25]; [@B26]; [@B17]; [@B13]) studies reported drug resistance in patients who experienced virologic failure. Among these studies, we found that three studies reported that drug resistance mutations were associated with PIs/r in patients who failed antiretroviral therapy. Drug resistance was mainly found to occur for RAL and NRTIs. In addition, relevant mutations were found at Q148R/Q, T97T/A, 155H, 143R, and 140S+148H for RAL and at M184V, 70R, 67N, and 65R for NRTIs. Detailed information is shown in [**Table 2**](#T2){ref-type="table"}.

###### 

Effects of the simplified and traditional treatment regimens on drug resistance.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study name   Mutation site                     Description                                          
  ------------ --------------------------------- ------------------ --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B16]       Q148R/Q, T97T/A, N155H            Not given          Not given                         Of the patients who failed antiretroviral therapy:\
                                                                                                      36.3% (4/11) of patients were found to have an RAL-resistant mutation;\
                                                                                                      9.1% (1/11) of patients developed phenotypic resistance to RAL without any evidence of an RAL-drug-resistant mutation;\
                                                                                                      No patient had ATV or NRTI resistance (genotypic or phenotypic).

  [@B28]       G163R, N155H, T97A                Not given          M184V, N155H                      3.96% (4/101) LPV/r + RAL and 2.86% LPV/r + TDF/FTC (3/105) met the criteria for resistance testing of virologic failure.

  [@B25]       143R, 155H, and 140S+148H         82A, 46I and 76V   70R, 67N, and 65R                 In the patients who failed antiretroviral therapy, there was intermediate- or high-level resistance in 2% of patients in the NRTI group and 1% in the RAL group.

  [@B1]        Not given                         Not given          Not given                         Not given

  [@B11]       T66A, T143A/T143C/T143H, A 155H   Not given          M184V, 69 insertion complex\      Of the patients who failed antiretroviral therapy, RAL and NRTI resistance was found in 14.9% and 14.0% of patients, respectively. No PI mutations were recorded.
                                                                    151 insertion complex             

  [@B17]       T66A, T97A, T143C/A, A155H        M46I, L76V, V82A   M184V, TAMS, T69A                 13.3% (6/50) of participants showed NRTI-resistant mutations;\
                                                                                                      15.56% (7/50) of participants showed PI-resistant mutations;\
                                                                                                      26.09% (12/46) of participants showed RAL-resistant mutations

  [@B26]       A155H                             Not given          L65A                              Of the patients who failed antiretroviral therapy, 17.2% (5/29) had resistance to integrase, and 3.4% (1/29) had resistance to NRTI.

  [@B13]       Y143R, N155H, Q148H, T97A,        46I/L54V,          70R, 67N, 215Y, 41L, TAM1, 151M   3% (10/321) of participants (viral loads \<1000 copies/mL) showed NRTI-resistant mutations\
                                                                                                      2% (7/321) of participants (viral loads \<1000 copies/mL) showed PI-resistant mutations;\
                                                                                                      7% (10/321) of participants (viral loads \<1000 copies/mL) showed RAL-resistant mutations
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RAL, raltegravir. NRTI, nucleoside or nucleotide reverse transcriptase inhibitor. PIs/r, ritonavir-boosted protease inhibitor.

### Adherence and Mortality {#s3_3_5}

Poor adherence is one of the important reasons for antiretroviral therapy failure, and it is also one of the important factors for drug resistance. Four studies ([@B11]; [@B25]; [@B1]; [@B13]) evaluated adherence. The investigation of adherence was mainly in the form of an adherence questionnaire. There were significant differences in adherence between the DT and TT groups \[risk ratio 1.03, 95% CI (1.01, 1.06), P \< 0.01\]. Six studies ([@B11]; [@B25]; [@B26]; [@B1]; [@B17]; [@B13]), which involved 4,117 participants, reported comparisons of the mortality between two different groups. The risk ratio of mortality in the two groups at the last visit was 0.84 (95% CI 0.63--1.12), and there were no significant differences between any regimens (P = 0.24) **(** [**Figure 6**](#f6){ref-type="fig"} **).**

![Forest plots comparing adherence and mortality between the two regimens. (1) RAL = raltegravir. PIs/r = ritonavir-boosted protease inhibitor. NRTI = nucleoside or nucleotide reverse transcriptase inhibitor. (2) Study item displayed as the first author with the publication year. (3) I^2^ and P are the criteria of the heterogeneity test, with the ---◆---pooled odds ratio, ---¦--- odds ratio and 95% confidence interval.](fphar-10-01225-g006){#f6}

Discussion {#s4}
==========

Until recently, antiretroviral therapy has typically consisted of two reverse-transcriptase inhibitors and a PI/r or an NRTI for treatment-naive and treatment-experience people living with HIV/AIDS (PLWHA) ([@B2]). For maintaining long-term suppressive therapy with the best quality of life, a relatively simple and tolerable regimen is needed ([@B1]). Drug resistance threatens the long-term efficacy of ART in both developed and developing countries and has led to the development of a new class of drugs termed integrase inhibitors ([@B30]; [@B31]; [@B12]). RAL, which suppresses the RNA replication of HIV-1 strains, appeared on the market in 2007 and has quickly become a staple of the anti-HIV-1 drug arsenal. The clinical use of RAL represents a milestone that appeared 10 years after ART was introduced to treat AIDS. A PI/r plus RAL was included as an alternative regimen in the 2016 WHO treatment guidelines ([@B34]). The WHO-preferred PI/r are atazanavir, lopinavir, and darunavir on the basis of efficacy and tolerability ([@B32]).

This meta-analysis of eight RCTs involving 4,327 PLWHA assessed the clinical value of the effect of DT group versus TT group. All of the studies were based on patients showing a posttreatment plasma HIV-1 RNA viral load \<50 copies/mL. According to the viral suppression outcome, DT group is noninferior to TT group at 48 and 96 weeks, whereas the DT regimen was superior to the TT regimen at 24 weeks. The cause of this may be the patient drug sensitivity and high adherence. For the CD4 cell counts, the DT was superior to the TT at 48 weeks and 96 weeks. This indicated that DT group was better than TT group in terms of immunological reconstitution. While there was no clinical significance, the change in CD4 cell counts was 17.6 cell/mm^3^ and 26.5 cell/mm^3^ higher in the DT group than in the TT group at 48 weeks and 96 weeks, respectively. Grade 3 or 4 adverse events resulting from drug regimens have always been a primary focus. In this study, we found no significant difference in adverse events between the DT and TT groups at 96 weeks. At 48 weeks, the DT group had fewer adverse events than the TT group (P \< 0.01). The common adverse events in the DT group were fever, skin rash, neurological events, and headache ([@B28]; [@B25]; [@B17]; [@B13]). Clinicians should monitor these adverse events and treat them in real time to reduce the interruption of treatment due to adverse events. With respect to drug resistance, the relevant RAL mutation sites were mainly N155H, Q148H/K/R, G140S, Y143R, and T97A ([@B28]; [@B16] [@B11]; [@B25]; [@B26]; [@B17]; [@B13]). A patient may develop resistance with the occurrence of any two mutations. Three studies ([@B25]; [@B17]; [@B13]) mentioned PI (LPV)-resistance mutation sites, which were M46I, L76V, and V82A. In our review, we found that, despite the presence of mutations, there were few patients who failed ART due to RAL or PIs resistance. However, multidrug combinations and the pill burden of such programs will lead to poor treatment compliance issues. Our review found that RAL plus PIs/r could enhance the adherence of patients. To a great extent, reducing the number of patients with poor adherence and antiretroviral failure may prolong the life of patients. At the same time, drugs with a high genetic barrier can be used as the main treatment to avoid premature cessation due to drug resistance and untimely treatment. Although RAL exhibits rapid, efficient, and long-lasting antiretroviral activity, it is expensive and is currently not included on the list of free antiretroviral drugs in China; as such, RAL is bound to be a heavy economic burden to most AIDS patients.

Our study has some limitations. First, the number of included studies in our review was too low. The analysis of some important outcomes, including mortality and the number of and reason for discontinuations, was limited by a low number of events. Second, the varying numbers of participants brought some uncertainty to the research results. The statistical analysis will incorporate a certain deviation, resulting in result errors. Finally, the studies were from various settings, including low-income, middle-income, and high-income countries; most were from low-income countries. Although this is an external factor, we cannot ignore the internal effects of external factors.

Increasing attention has been directed toward the development of drugs for PLWHA who have failed antiretroviral therapy. This meta-analysis indicates that combinations of RAL with PIs/r not only decrease the plasma HIV-1 RNA load and enhance the CD4 cell counts but also result in fewer side effects. Additionally, there was no obvious drug resistance to these combinations. In summary, RAL combined with PIs/r could be a beneficial and safe therapeutic choice for PLWHA, and higher adherence rates and realization of immune reconstruction could improve quality of life and enhance patient preference; this strategy is worthy of clinical promotion.
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